Biotech Values

[DewDiligence]

The three FoB compounds are not at the same stage of development; the first two compounds, which were already selected at the time of the deal signing in Dec 2011, are further advanced than the third compound, which was selected in Aug 2012. Moreover, BAX has merely taken an option on compound #3 and has not yet formally licensed it.

Please note that BAX and MNTA have not disclosed the identities of these three compounds—it is merely my supposition that they are Humira, Orencia, and Erbitux (although I would be willing to bet that at least two of these three are correct).